Pain Therapeutics (NASDAQ:PTIE) shares rose 5.1% during mid-day trading on Monday . The stock traded as high as $2.67 and last traded at $2.67, with a volume of 84,069 shares traded. The stock had previously closed at $2.54.

Separately, Zacks Investment Research upgraded shares of Pain Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, May 31st.

The firm’s market cap is $119.97 million. The firm’s 50 day moving average price is $2.44 and its 200-day moving average price is $2.21.

Pain Therapeutics (NASDAQ:PTIE) last released its earnings results on Tuesday, July 19th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.07. Equities analysts expect that Pain Therapeutics will post ($0.42) EPS for the current year.

Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.